$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

$mrsn Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000162828023037193 Filed on November 07, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$10.70M	$7.698M
YoY Change	-27.14%	38.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.13M	$12.89M
YoY Change	-31.55%	-11.55%
% of Gross Profit
Research & Development	$21.50M	$30.53M
YoY Change	-52.97%	-39.71%
% of Gross Profit
Depreciation & Amortization	$447.0K	$430.0K
YoY Change	58.51%	101.88%
% of Gross Profit
Operating Expenses	$31.63M	$51.64M
YoY Change	-47.73%	-20.81%
Operating Profit
YoY Change
Interest Expense	$1.883M	$1.017M
YoY Change	108.76%	15.57%
% of Operating Profit
Other Income/Expense, Net		$2.285M
YoY Change		-1428.49%
Pretax Income	-$19.54M	-$41.66M
YoY Change	-56.5%	-30.35%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$19.54M	-$41.70M
YoY Change	-56.5%	-30.27%
Net Earnings / Revenue	-182.64%	-541.7%
Basic Earnings Per Share		-$0.35
Diluted Earnings Per Share	-$0.16	-$0.35
COMMON SHARES
Basic Shares Outstanding	120.6M shares	120.5M shares
Diluted Shares Outstanding		120.5M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$209.1M	$241.0M
YoY Change	-25.52%	-16.93%
Cash & Equivalents	$174.6M	$186.3M
Short-Term Investments	$34.52M	$54.70M
Other Short-Term Assets	$4.973M	$8.800M
YoY Change	-41.54%	-11.21%
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$214.1M	$249.7M
YoY Change	-32.94%	-16.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.831M	$12.70M
YoY Change	-3.86%	-10.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$478.0K	$478.0K
YoY Change	-27.69%	-22.4%
Total Long-Term Assets	$12.00M	$13.17M
YoY Change	-20.62%	-11.12%
TOTAL ASSETS
Total Short-Term Assets	$214.1M	$249.7M
Total Long-Term Assets	$12.00M	$13.17M
Total Assets	$226.1M	$262.9M
YoY Change	-32.39%	-16.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.319M	$12.95M
YoY Change	-47.54%	-5.72%
Accrued Expenses	$21.90M	$29.32M
YoY Change	-49.29%	-28.84%
Deferred Revenue	$28.15M	$21.59M
YoY Change	-8.05%	-30.18%
Short-Term Debt	$2.083M	$0.00
YoY Change
Long-Term Debt Due	$2.083M	$0.00
YoY Change
Total Short-Term Liabilities	$63.64M	$67.93M
YoY Change	-30.48%	-23.49%
LONG-TERM LIABILITIES
Long-Term Debt	$23.15M	$25.00M
YoY Change	-7.14%	0.0%
Other Long-Term Liabilities	$55.00K	$67.00K
YoY Change	-72.91%	-74.81%
Total Long-Term Liabilities	$23.20M	$25.07M
YoY Change	-7.68%	-0.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$63.64M	$67.93M
Total Long-Term Liabilities	$23.20M	$25.07M
Total Liabilities	$189.2M	$210.7M
YoY Change	-21.93%	-6.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$826.4M	-$806.8M
YoY Change	26.23%	32.31%
Common Stock	$863.3M	$859.0M
YoY Change	15.58%	22.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.90M	$52.20M
YoY Change
Total Liabilities & Shareholders Equity	$226.1M	$262.9M
YoY Change	-32.39%	-16.5%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$19.54M	-$41.70M
YoY Change	-56.5%	-30.27%
Depreciation, Depletion And Amortization	$447.0K	$430.0K
YoY Change	58.51%	101.88%
Cash From Operating Activities	-$31.96M	-$46.08M
YoY Change	-37.61%	-184.4%
INVESTING ACTIVITIES
Capital Expenditures	$386.0K	$470.0K
YoY Change	-50.83%	-210.33%
Acquisitions
YoY Change
Other Investing Activities	$20.53M	$104.3M
YoY Change	-146.0%	-748.93%
Cash From Investing Activities	$20.15M	$103.8M
YoY Change	-144.35%	-729.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	92.00K	-150.0K
YoY Change	-99.78%	-101.41%
NET CHANGE
Cash From Operating Activities	-31.96M	-46.08M
Cash From Investing Activities	20.15M	103.8M
Cash From Financing Activities	92.00K	-150.0K
Net Change In Cash	-11.72M	57.55M
YoY Change	-78.76%	18.07%
FREE CASH FLOW
Cash From Operating Activities	-$31.96M	-$46.08M
Capital Expenditures	$386.0K	$470.0K
Free Cash Flow	-$32.35M	-$46.55M
YoY Change	-37.81%	-184.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30531000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50639000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12894000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14573000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	8214000	usd
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1017000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	880000	usd
	us-gaap	Interest Expense InterestExpense	3025000	usd
	us-gaap	Interest Expense InterestExpense	2364000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152126000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41656000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-41656000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-159288000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-159288000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97641936	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97641936	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114595910	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114595910	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91173989	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91173989	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121741000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60462000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5485000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47258000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	140526000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	39899000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	606000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5348000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-52219000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	134034000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10626000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	110000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5375000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-105000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-59811000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	90229000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21795000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	71875000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	393000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	963000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6643000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-61000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-54307000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	89800000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4001000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	50000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-41656000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	52195000	usd
	us-gaap	Profit Loss ProfitLoss	-152126000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1070000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4239000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	17051000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-536000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-574000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	244000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2459000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-659000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1153000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-13617000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11848000	usd
	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	2051000	usd
	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	2127000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2186000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1861000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14557000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	128397000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136920000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1866000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	232970000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	54000000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	131453000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	159878000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1782000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1412000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	99735000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107290000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	93539000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	110954000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	427000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	206000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	963000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	606000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	196000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	207000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	94583000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111559000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57398000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6135000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186761000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184560000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	442000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	407000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2508000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1746000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	298000	usd
CY2023Q3	mrsn	Number Of Additional Preclinical Candidates NumberOfAdditionalPreclinicalCandidates	2	candidate
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-41700000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-59800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152100000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-806800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, management’s judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk and Off-balance Sheet RiskFinancial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	147653000	usd
	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	1710000	usd
	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	16267000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	133096000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3944000	usd
	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	140000000	usd
	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	11603000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	132341000	usd
CY2023Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4503000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4919000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	17963000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	32000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128885000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186283000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177947000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	184082000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184560000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	54702000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	54703000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	151980000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	31000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	151827000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	5	security
CY2023Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	29900000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q3	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	8544000	usd
CY2022Q4	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	14822000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7168000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11558000	usd
CY2023Q3	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	4250000	usd
CY2022Q4	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	11536000	usd
CY2023Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	4190000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2023Q3	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	3062000	usd
CY2022Q4	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	2767000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1583000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1865000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	524000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	636000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29321000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43184000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25000000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	259000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	414000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	25155000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.05
CY2013	mrsn	Contractual Life Of Warrants ContractualLifeOfWarrants	P10Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
	mrsn	Warrants Exercised In Period WarrantsExercisedInPeriod	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16300491	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11944664	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16300491	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11944664	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10051283	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3972166	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.80
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97596	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1747727	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.62
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12178126	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.13
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7130744	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4001000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5375000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17051000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16208000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4001000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5375000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17051000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16208000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.044
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.038
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M9D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.13
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16300491	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16300491	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12418052	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12418052	shares
CY2023Q3	mrsn	Restructuring And Related Cost Number Of Positions To Be Eliminated Percent RestructuringAndRelatedCostNumberOfPositionsToBeEliminatedPercent	0.50
CY2023Q3	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	8214000	usd
	us-gaap	Restructuring Charges RestructuringCharges	8214000	usd
CY2023Q3	us-gaap	Restructuring Charges RestructuringCharges	8214000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
	mrsn	Restructuring Charges Additional Expense RestructuringChargesAdditionalExpense	6797000	usd
	us-gaap	Payments For Restructuring PaymentsForRestructuring	2435000	usd
	us-gaap	Restructuring Reserve Translation And Other Adjustment RestructuringReserveTranslationAndOtherAdjustment	-172000	usd
CY2023Q3	us-gaap	Restructuring Reserve RestructuringReserve	4190000	usd

Files In Submission

Name	View Source	Status
mrsn-20230930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
mrsn-20230930_def.xml	Edgar Link	unprocessable
mrsn-20230930_cal.xml	Edgar Link	unprocessable
0001628280-23-037193-index-headers.html	Edgar Link	pending
0001628280-23-037193-index.html	Edgar Link	pending
0001628280-23-037193.txt	Edgar Link	pending
0001628280-23-037193-xbrl.zip	Edgar Link	pending
exhibit101-amendmentno1tor.htm	Edgar Link	pending
exhibit102-amendmentno2tor.htm	Edgar Link	pending
exhibit103-aprotopapasreti.htm	Edgar Link	pending
exhibit104-mhuberofferlett.htm	Edgar Link	pending
exhibit105-ayangletteragre.htm	Edgar Link	pending
exhibit31110-qfy2023q3.htm	Edgar Link	pending
exhibit31210-qfy2023q3.htm	Edgar Link	pending
exhibit32110-qfy2023q3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrsn-20230930.htm	Edgar Link	pending
mrsn-20230930.xsd	Edgar Link	pending
mrsnlogo.gif	Edgar Link	pending
mrsnlogob.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
mrsn-20230930_pre.xml	Edgar Link	unprocessable
mrsn-20230930_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

2023 Q4 Form 10-Q Financial Statement

#000162828023037193 Filed on November 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN Mersana Therapeutics, Inc. Stock $mrsn

2023 Q4 Form 10-Q Financial Statement

#000162828023037193 Filed on November 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn